Therapeutic applications of catalytic antisense RNAs (ribozymes)
- PMID: 9383577
- DOI: 10.1002/9780470515396.ch14
Therapeutic applications of catalytic antisense RNAs (ribozymes)
Abstract
Ribozymes have progressed from an intriguing subject of scientific study to therapeutic agents for the potential treatment of a fatal and devastating viral infection. Despite this rapid road to clinical trials, there are many unexplored avenues that should be examined to improve the intracellular effectiveness of ribozymes. Since ribozymes are RNA molecules, the cellular rules governing RNA partitioning and stability can be applied to these molecules to make them more effective therapeutic agents. Future, successful therapeutic ribozyme applications will depend upon increasing our knowledge of RNA metabolism and movement, and applying this knowledge to the design of ribozymes. This chapter discusses experimental approaches towards this goal as well as recent progress in the application of a pair of hammerhead ribozymes for the clinical treatment of HIV1 infection.
Similar articles
-
Exploring the use of antisense, enzymatic RNA molecules (ribozymes) as therapeutic agents.Antisense Res Dev. 1991 Fall;1(3):285-8. Antisense Res Dev. 1991. PMID: 1821650 Review.
-
Therapeutic ribozymes: principles and applications.BioDrugs. 1998 Jan;9(1):1-10. doi: 10.2165/00063030-199809010-00001. BioDrugs. 1998. PMID: 18020552
-
HIV-1 TAR as anchoring site for optimized catalytic RNAs.Biol Chem. 2003 Mar;384(3):343-50. doi: 10.1515/BC.2003.040. Biol Chem. 2003. PMID: 12715885
-
Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection.Inflamm Res. 1995 Jan;44(1):11-5. doi: 10.1007/BF01630480. Inflamm Res. 1995. PMID: 7664023 Review. No abstract available.
-
Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes.Front Biosci. 2006 Sep 1;11:2940-8. doi: 10.2741/2023. Front Biosci. 2006. PMID: 16720366
Cited by
-
Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy.Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11488-93. doi: 10.1073/pnas.210319397. Proc Natl Acad Sci U S A. 2000. PMID: 11005848 Free PMC article.
-
Intracellular ribozyme-catalyzed trans-cleavage of RNA monitored by fluorescence resonance energy transfer.RNA. 2000 Apr;6(4):628-37. doi: 10.1017/s1355838200990964. RNA. 2000. PMID: 10786853 Free PMC article.
-
Rapid kinetic characterization of hammerhead ribozymes by real-time monitoring of fluorescence resonance energy transfer (FRET).RNA. 1999 Oct;5(10):1348-56. doi: 10.1017/s1355838299991185. RNA. 1999. PMID: 10573125 Free PMC article.
-
Down-regulation of the M6P/IGF-II receptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes.BMC Cell Biol. 2004 Apr 28;5:15. doi: 10.1186/1471-2121-5-15. BMC Cell Biol. 2004. PMID: 15115542 Free PMC article.
-
New modalities in oncology: ribozymes.Proc (Bayl Univ Med Cent). 2002 Jul;15(3):247-9. doi: 10.1080/08998280.2002.11927847. Proc (Bayl Univ Med Cent). 2002. PMID: 16333444 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources